Insights

At the 2024 Great Debates & Updates in Hematologic Malignancies, Joshua Richter, MD, explores the role of minimal residual disease in multiple myeloma treatment strategies, addressing whether it should be used to make clinical decisions for...

At the Lymphoma, Leukemia & Myeloma Congress in New York, John Allan, MD, discusses novel updates in the chronic lymphocytic leukemia treatment landscape, highlighting studies that focused on BTK inhibitor combination treatments.

At the Lymphoma, Leukemia & Myeloma Congress in New York, Jennifer Amengual, MD, discusses new approvals and treatment strategies for older patients with aggressive lymphoma who are ineligible for CAR T-cell therapy.

At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, discusses the introduction of chemotherapy-free novel agents for the treatment of patients with mantle cell lymphoma.

At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, provides insight into the use of BTK inhibitors in the frontline mantle cell lymphoma treatment space.

At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, discusses advances in chemoimmunotherapy for the first-line treatment of patients with mantle cell lymphoma.

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Nicole Lamanna, MD, discusses the potential for the use of non-covalent BTK inhibitor pirtobrutinib in treatment regimens for patients with chronic lymphocytic leukemia.

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Neil E. Kay, MD, discusses the pathobiology and management of double refractory CLL.

Andrew Zelenetz, MD, discusses up and coming treatment developments on the horizon within the large-cell lymphoma research space, focusing on the importance of immunotherapy.

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, University of California – San Francisco, San Francisco, California, discusses the role of bispecific antibodies in the treatment of patients with multiple...